Tag: Africa

SAN JOSE, Calif., March 19, 2024 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM), has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2024.

This year’s list shines a spotlight on businesses that are shaping industry and culture through their innovations. These organizations are setting new standards and achieving remarkable milestones in all sectors of the economy. Alongside the World’s 50 Most Innovative Companies, Fast Company recognizes 606 organizations across 58 sectors and regions.

“At Zoom, we continue to innovate rapidly and are doubling down on our commitment to offering an AI-powered collaboration platform that delivers limitless human connection, reimagines teamwork, and strengthens customer connections,” said Smita Hashim, chief product officer at Zoom. “Fast Company’s recognition further validates our mission and dedication to providing our customers with choice and a high-quality, open collaboration platform powered by AI that just works.”

Zoom AI Companion drives impact in the workplace
In 2023, Zoom launched AI Companion, an AI-powered assistant that is designed to empower collaboration and unlock users’ potential across the Zoom platform by delivering critical information, automating routine tasks, and helping users stay informed. AI Companion utilizes Zoom’s unique federated approach to AI, which is designed to deliver high-quality results by dynamically incorporating Zoom’s artificial intelligence model as well as third-party artificial intelligence models. With this approach, Zoom can offer AI Companion across the Zoom platform and at no additional cost*, helping to democratize AI by making it accessible to all employees within an organization.

AI Companion delivers on Zoom’s commitment to helping businesses drive more effective collaboration and productivity through its platform, including Meetings, Team Chat, Notes, Docs, Whiteboard, Mail and Calendar, and Clips. Users can stay within one platform to help make work, less work.

Users can benefit from the multitude of AI Companion capabilities that can assist with repetitive tasks, helping to save users time and increase efficiency, including:

• Receive an automated meeting summary after the meeting to share with attendees and those who were unable to attend.
• Catch up quickly in a meeting without disrupting the meeting flow by discreetly submitting questions via the in-meeting AI Companion side panel.
• Watch recordings through highlights and smart chapters, and review summaries and next steps, to quickly catch up on a missed meeting.
• Receive help to quickly draft messages based on the context of a Team Chat thread, and ask AI Companion to adjust tone and length.
• Catch up on long chat threads through generative AI summarization.
• Get help generating ideas on a digital whiteboard and organizing them into categories.
• Receive AI-generated draft email suggestions based on the context of an email thread.

Additional capabilities are expected to be announced in the coming weeks.

The World’s Most Innovative Companies stands as Fast Company‘s hallmark franchise and one of its most anticipated editorial efforts of the year.

Fast Company‘s editors and writers identified the companies driving progress around the world and across industries, evaluating thousands of submissions through a competitive application process. The result is a globe-spanning guide to innovation today, from early-stage startups to some of the most valuable companies in the world. Fast Company’s Most Innovative Companies package is available online, as well as in-app form via iTunes, and on newsstands beginning March 26. The hashtag is #FCMostInnovative.

“Our list of the Most Innovative Companies is both a comprehensive look at the innovation economy and a snapshot of the business trends that defined the year,” said Fast Company editor-in-chief Brendan Vaughan. “We saw extraordinary innovation across the board in 2023, but we also saw a handful of clear patterns: the growing footprint and impact of AI, the triumphant return of live events, and great leaps forward in climate tech. We face daunting challenges on many fronts, but the solutions we celebrate in MIC give me plenty of hope about the future.”

Fast Company will host the Most Innovative Companies Summit and Gala on May 16. The summit features a morning and afternoon of inspiring content, followed by a creative black-tie gala including networking, a seated dinner, and an honoree presentation. This event celebrates the Most Innovative Companies honorees and provides an inside look at cutting-edge business trends and what it takes to innovate in 2024.

About Zoom
Zoom is an all-in-one intelligent collaboration platform that makes connecting easier, more immersive, and more dynamic for businesses and individuals. Zoom technology puts people at the center, enabling meaningful connections, facilitating modern collaboration, and driving human innovation through solutions like team chat, phone, meetings, omnichannel cloud contact center, smart recordings, whiteboard, and more, in one offering. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more info at zoom.com.

ABOUT FAST COMPANY
Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication Inc., and can be found online at www.fastcompany.com.

Zoom Public Relations
Bridget Moriarty
press@zoom.us

GlobeNewswire Distribution ID 9065842

https://www.globenewswire.com/NewsRoom/AttachmentNg/d32f0dd2-5510-4922-aead-62719b31e294

VALENCIA, Spain, March 19, 2024 (GLOBE NEWSWIRE) — The European Academy of Allergy and Clinical Immunology (EAACI), with a membership of over 16,000 from 125 countries, annually orchestrates its congress to unveil the latest research and innovative advancements in allergy and clinical immunology. We are thrilled to extend a warm invitation to you for the upcoming EAACI Congress 2024, scheduled to take place in Valencia from May 31st to June 3rd, 2024.
In a bid to provide you with an immersive experience, we will offer you a dedicated press area where you can schedule interviews with leading physicians and researchers in the field.

Register for free

LOCATION:
Our venue, Feria de Valencia, is a prestigious convention and exhibition centre known for its modernity and versatility. Moreover, the event will take place at the vibrant city of Valencia, which is celebrated for its harmonious coexistence of tradition and modernity.

PROGRAMME:
The Scientific Programme will encompass the entire spectrum of Allergy and Clinical Immunology. Under the overarching theme of “Revolutionizing Patient Care Through the Power of Data Science” our congress promises to be an extraordinary intellectual journey. We are delighted to present a diverse and dynamic program featuring over 150 scientific sessions meticulously crafted to inform and inspire.

CONGRESS TOPICS:

• Environmental Science: Join the conversation to understand how environmental issues have significantly increased allergic diseases such as bronchial asthma, allergic rhinoconjunctivitis, and atopic dermatitis in industrialized countries in recent years.

• Food Allergy: A major public health issue with rising prevalence in metropolitan areas and a significant impact on the lives of patients with allergies. We will discuss about cutting-edge approaches to managing food allergies.

• Innovations in Immunotherapy: Discover revolutionary developments in allergen immunotherapy, an area transforming the landscape of allergy treatment. Learn about the latest advances in the application of immunotherapy.

• Pediatric Allergies: Explore the increasing incidence of allergies among children worldwide and the factors contributing to this phenomenon. Gain insights into global initiatives addressing pediatric allergies and collaborative efforts to enhance the well-being of young individuals affected by allergies.

KOLs of EAACI
In this link, you’ll find our dedicated committee, comprised of renowned doctors and scientists from various nationalities, available for interviews and reports.

PRESS RELEASE: https://eaaci.org/news/

SOCIAL MEDIA:

Podcast: https://linktr.ee/eaaci
LinkedIn: https://www.linkedin.com/company/eaaci/
Instagram: @eaaciHQ
Twitter: @EAACI_HQ
Facebook: https://www.facebook.com/EAACI
CONTACT: communications@eaaci.org

HASHTAGS: #EAACIannualCongress

GlobeNewswire Distribution ID 1000929992

NEW YORK, N.Y., March 12, 2024 (GLOBE NEWSWIRE) — The Women in the Digital Economy Fund (WiDEF), a five-year $60.5 million investment to accelerate progress on closing the global gender digital divide, announces its first call for applications with recorded remarks from the United States Agency for International Development (USAID) Administrator Samantha Power.

Founded by USAID and the Bill & Melinda Gates Foundation—and first announced by U.S. Vice President Kamala Harris in Accra, Ghana in March 2023—WiDEF will now begin identifying, funding, and accelerating investment in proven solutions to close the gender digital divide.

​”The gender digital divide hinders development progress—ingraining existing inequities into the fabric of societies of the future, creating a self-perpetuating cycle that drives further disparities. We need a future in which women are empowered to participate as equal citizens in our increasingly digital world. We look forward to working together to achieve that vision,” said Samantha Power, Administrator, USAID.

“I’m proud of our support for the Women in the Digital Economy Fund. Overcoming the gender digital divide is crucial to unlock the potential of women in the digital era. By increasing women’s participation in digital technology, we’re aiming not just to change their status from consumers to creators and leaders; we’re working to forge a path to a future where everyone benefits,” said Anita Zaidi, President of the Gender Equality Division at the Bill & Melinda Gates Foundation.

This event, which brought together leaders from across the public and private sectors and civil society worldwide, was an opportunity to celebrate the start of this effort and learn about how WiDEF will implement its ambitious vision. Representing the Biden-Harris Administration at today’s kickoff event was Rachel Vogelstein, White House Gender Policy Council Deputy Director.

Advancing access to digital technology for all women and girls is critical to achieving the United Nations’ Sustainable Development Goals. This will help ensure that everyone has access to economic opportunities and advancement as well as government services, education, and healthcare.

In low- and middle-income countries, nearly one and a half billion women lack access to online services. Through 2022, there were 259 million more men than women globally using the internet; a gap that has cost the global economy an estimated $1 trillion. Closing the gender digital divide would increase economic activity by an estimated $524 billion by 2025.

WiDEF is administered by consortium partners CARE, Global Digital Inclusion Partnership (GDIP), and the GSMA Foundation. The consortium will collaborate with industry-leading organizations to effectively engage local and global private sector actors and funders to advance a shared set of commitments to closing the gender digital divide.

“WiDEF is about putting millions of women at the center of connectivity and information programming. CARE brings our strength in locally led, gender-centered programming in over 100 countries to the effort. The consortium’s collective focus on technology, policy, and gender advocacy offers the greatest opportunity yet to create and sustain an internet that works for the women who could most benefit from it,” said Revi Sterling, WiDEF Technical Director and CARE Senior Technical Director, Digital Inclusion.

“Launching WiDEF is indeed a special moment, one that reflects real commitment and determination to address the stubborn gender digital divide and open the possibilities for women in the digital economy. GDIP is committed to women’s digital inclusion, and we look forward to advocating alongside our global partners to advance this collective effort,” said Sonia Jorge, GDIP Executive Director.

“Closing the gender digital divide has been at the centre of the GSMA Foundation’s work for over a decade, and we are extremely honoured to play an active role in the management of the Women in the Digital Economy Fund. We now look forward to receiving applications to the first round launched today, and to the further two rounds to be announced later this year, focused on large private sector actors, and India specifically,” said Max Cuvellier Giacomelli, Head of Mobile for Development, GSMA.

WiDEF will support and fund programs that advance digital access and affordability; develop relevant products and tools; provide digital literacy and skills training; promote online safety and security; and invest in sex-disaggregated data and research. It will support, wherever possible, women-led and gender transformative solutions, products, and tools and will invest heavily in ensuring the voices and institutions closest to the gender digital divide are central to the effort.

As part of today’s event, WiDEF announced the first call for applications, inviting local institutions worldwide to apply to receive WiDEF funding and support. Applications are due by May 6, 2024.

In addition to financial support from USAID and the Bill & Melinda Gates Foundation, funding is also being provided by Microsoft and the Korean International Cooperation Agency.

To learn more, email contact@widef.global, visit us online at widef.global or follow WiDEF on social media (Instagram, Facebook, LinkedIn and Twitter/X).

About CARE
Founded in 1945 with the creation of the CARE Package®, CARE is a leading humanitarian organization fighting global poverty. CARE places special focus on working alongside women and girls. Equipped with the proper resources, women and girls have the power to lift whole families and entire communities out of poverty. This year, CARE and partners worked in 109 countries implementing 1,671 poverty-fighting development and humanitarian aid projects and initiatives that reached 167,000,000 people. To learn more, visit www.care.org.

About GDIP
The Global Digital Inclusion Partnership (GDIP) is a coalition of public, private, and civil society organizations working to bring internet connectivity to the global majority and ensure everyone is meaningfully connected by 2030. Founded by a global team of experts who successfully championed affordable and meaningful connectivity around the world, GDIP advances digital opportunities to empower and support people’s lives and agency, leading to inclusive digital societies.

GSMA Mobile for Development Foundation
The GSMA Mobile for Development Foundation, Inc. (‘The GSMA Foundation’) brings together mobile operators, innovators, governments, and the international development community to realise the positive social, economic and climate impact of mobile technology, primarily in low- and middle-income countries. With funding from donors and the GSMA, the GSMA Foundation runs programmes that advance digital and financial inclusion – with a strong focus on gender inclusivity, climate action, humanitarian response, and investment in innovative digital solutions. Since 2007, these programmes have impacted the lives of over 220 million people.

Michael de Vulpillieres
CARE
+1 929 944 1582
usa.media@care.org

GlobeNewswire Distribution ID 9062253

Proposed divestiture of Endpoint Clinical and Fortrea Patient Access businesses further streamlines Fortrea’s strategic focus as a pure-play contract research organization

Creates standalone best-in-class Randomization and Trial Supply Management and Patient Access solutions positioned for differentiation and growth

DURHAM, N.C., March 11, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced it has signed a definitive agreement to divest assets relating to its Enabling Services segment, namely its Endpoint Clinical (“Endpoint”) and Fortrea Patient Access businesses, to Arsenal Capital Partners (“Arsenal”), a leading private equity firm specializing in building market-leading, technology-rich healthcare companies.

By divesting these businesses, Fortrea aims to advance the growth strategy and solutions of Endpoint and Fortrea Patient Access, positioning them for increased investment to accelerate the technology roadmap and further enhance operations to support best-in-class customer solutions and delivery. The remaining business of Fortrea will strengthen its focus on clinical development phases 1 through 4. Closing is targeted for the second quarter of 2024, subject to customary closing conditions and regulatory approvals, as well as the parties entering into certain services and operating agreements.

“Today marks a significant milestone in Fortrea’s ongoing journey, as we sharpen our focus on organically growing as a pure-play CRO, with added financial flexibility,” said Fortrea Chairman and CEO Tom Pike. “After undertaking a strategic review of our business, divesting Endpoint and Fortrea Patient Access aligns with the interests of our customers. Arsenal has extensive experience in building businesses that create systematic improvement in health outcomes, and I am confident that Endpoint and Fortrea Patient Access will be able to strengthen their market positions, nurture top-tier talent and invest in new capabilities and resources while delivering solutions that improve patients’ lives.”

“I am excited for this next chapter for Endpoint and Fortrea Patient Access,” said Sam Osman, president of Enabling Services at Fortrea, who will serve as the CEO of these businesses with Arsenal. “These businesses will be distinctively positioned to effectively manage the patient journey across clinical trials and into commercialization by driving patient access and adherence for approved therapies. Combining Arsenal’s deep investment acumen and leading industry operational expertise, I am confident the Endpoint and Fortrea Patient Access businesses are well positioned for growth and delivery of enhanced capabilities for patients and pharma sponsors. I look forward to our continued positive impact on healthcare.”

“Endpoint and Fortrea Patient Access have a proud, decades-long track record of market leadership in supporting clinical research and commercialization of innovative therapies. Arsenal takes pride in building organizations that meaningfully improve healthcare. We are excited to partner with management and employees to accelerate the growth of these two businesses,” said Gene Gorbach, an Investment Partner of Arsenal.

Dimitris Agrafiotis, Ph.D., Director of Digital, Analytics & AI at Arsenal said, “Endpoint and Fortrea Patient Access provide essential solutions that enable patients’ participation in clinical trials and access to therapies. I am delighted to support the talented team at Endpoint and Fortrea Patient Access. Together, we will further enhance the sophistication of technology capabilities that underpin these companies’ commitment to delivering the highest quality services to the pharmaceutical industry.”

Endpoint Clinical
Endpoint operates in the high growth eClinical market as a leading provider of Randomization and Trial Supply Management (RTSM) solutions to biopharmaceutical and CRO customers with expertise in serving complex and late-stage clinical trials. For more than 15 years, Endpoint has had a successful track record of effectively supporting more than 1,750 clinical trials involving 875,000 patients across 90 countries and has cultivated a blue-chip customer base and nurtured long-standing strategic relationships.

Fortrea Patient Access
Fortrea Patient Access is a scaled leader in the HUB services and patient access market, serving the biopharmaceutical industry with comprehensive patient support, product access, affordability and adherence solutions for more than 30 years. Further advanced by its recently expanded non-commercial specialty pharmacy, FortreaRx, to support enhanced distribution of cold-chain and ambient free goods products, Fortrea Patient Access is committed to driving patient outcomes and improving healthcare accessibility through its extensive experience while currently supporting more than 2.5 million patients and over 100 unique brands across more than 25 disease indications.

Arsenal Capital Partners
Arsenal Capital Partners is a leading private equity investment firm that specializes in building market-leading industrial growth and healthcare companies. Since its inception in 2000, Arsenal has raised institutional equity investment funds totaling over $10 billion, completed more than 290 platform and add-on acquisitions, and achieved more than 35 realizations. The firm works with management teams to build strategically important companies with leading market positions, high growth, and high value-add.  For more information, visit www.arsenalcapital.com.

Advisors
Barclays is serving as exclusive financial advisor to Fortrea, and Smith Anderson is serving as its legal counsel. Sidley Austin LLP served as Arsenal’s legal counsel.

Earnings Call and Replay
Fortrea will discuss the divestiture announcement on its fourth quarter 2023 earnings conference call, which will be held today at 9:00 am ET. The conference can be accessed through the Fortrea Investor Relations website or the following earnings webcast link. To avoid potential delays, please join at least 10 minutes prior to the start of the call. A replay of the live conference call will be available shortly after the conclusion of the event and accessible on the events and presentations section of the Fortrea website. A supplemental slide presentation will also be available on the Fortrea Investor Relations website prior to the start of the call.

About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, consulting services, differentiated technology-enabled trial solutions and post-approval services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of about 18,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the anticipated benefits of the transaction, including future financial and operating performance, and the anticipated timing for completing the transaction. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “guidance,” “expect,” “assume,” “anticipate,” “intend,” “plan,” “forecast,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results could differ materially from these forward looking statements due to a number of factors, including, but not limited to: satisfaction of the conditions precedent to consummation of the proposed divestiture of Endpoint Clinical and Fortrea Patient Access businesses transaction, including the ability to secure regulatory approvals, and the Company’s ability to complete the transaction in a timely manner or at all; the possibility that the transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; the parties’ ability to meet expectations regarding the accounting and tax treatments of the proposed transaction; and other factors described from time to time in documents that the Company files with the SEC. For a further discussion of the risks relating to the Company’s business, see the “Risk Factors” Section of the Company’s Registration Statement on Form 10, as filed with the Securities and Exchange Commission (the “SEC”), as such factors may be amended or updated from time to time in the Company’s subsequent periodic and other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included or incorporated by reference in this report and in the Company’s filings with the SEC. All forward-looking statements are made only as of the date of this report and the Company does not undertake any obligation, other than as may be required by law, to update or revise any forward-looking statements to reflect future events or developments.

Fortrea Contacts:
Hima Inguva (Investors) – 877-495-0816, hima.inguva@fortrea.com
Sue Zaranek (Media) – 919-943-5422, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com

Arsenal Contact:
Jackie Schofield at  pro-Arsenal@prosek.com

GlobeNewswire Distribution ID 9061141

Appoints Michael Bronstein as Scientific Advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing a hub for world-class TechBio talent in the heart of King’s Cross neighborhood

LONDON, March 11, 2024 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced plans to open a new office in London’s vibrant King’s Cross neighborhood. Set to formally open in June 2024, the site will provide Recursion and Valence Labs, the company’s artificial intelligence research engine, access to world-class talent across Europe’s rapidly growing TechBio sector and embed Recursion in a thriving innovation ecosystem of leading technology and life science companies.

“As Recursion continues to lead and define the TechBio industry, it’s critical we hire the best possible talent, much of which is located in Europe,” said Chris Gibson, Ph.D., Co-founder and CEO at Recursion. “London stood out as an ideal location given its brilliant and interdisciplinary talent across the fields of technology, biology and chemistry. It’s also the epicenter for the rapidly growing TechBio sector in Europe, where leading technology and life science companies like Google and Merck both sit within walking distance of our new Recursion site. I look forward to expanding our operations in Europe and hiring many new Recursionauts who will help us advance our mission of decoding biology to radically improve lives.”

To support Recursion’s leadership in TechBio and entry into London, the company is excited to announce the addition of Michael Bronstein, DeepMind Professor of Artificial Intelligence at Oxford University, as a Scientific Advisor. Professor Bronstein is a world leader in geometric deep learning, graph neural networks, and protein design. Professor Bronstein joins AI luminary Professor Yoshua Bengio in supporting Recursion and Valence Labs in the development of state-of-the-art AI models to support the industrialization of drug discovery.

“Recursion is leading the field in advancing cutting-edge AI research for real-world applications with the potential to radically improve lives, and I’m honoured to join them in their mission,” said Prof Michael Bronstein. “I have collaborated with Valence prior to their acquisition by Recursion, and I look forward to continuing to work with the team to advance this important work, especially as Recursion continues to grow in London.”

Recursion’s 6,700 square foot London office will be located at 3 Pancras Square, King’s Cross London. The building is part of a 67-acre redevelopment project in the heart of King’s Cross, with over 4.5 million square feet of office space. Located within a 3-minute walk from King’s Cross Station and St. Pancras International, the site offers excellent transit access. The building includes an onsite cafe, bicycle storage, showers, prayer room and mothers room. In line with Recursion’s commitment to sustainability, the building meets the requirements for an “Excellent” rating by BREEAM building standards and is linked to a site-wide district heating and cooling network that results in net-zero carbon emissions.

“The UK Government’s plan for attracting more inward investment into the UK is working. Recursion’s investment is yet another vote of confidence in the UK, our top talent and our amazing tech and life sciences industries,” said Investment Minister Lord Johnson. “I’m delighted Recursion has chosen London, and we’ll continue to do everything we can to ensure the UK remains the top choice for investments like this.”

Today, Recursion has over 500 employees with a near-equal mix of life scientists and technologists across sites in Salt Lake City, Toronto, Montréal, and the San Francisco Bay Area. Recursion’s new London office will serve as an extension of both Recursion and Valence Labs’ teams. To launch recruiting efforts for the new site, Recursion has opened multiple new roles across technology and biology functions with immediate plans to hire the first 20 people to be based out of the new London office. Recursion and Valence Labs will also host a TechBio Mixer tomorrow, March 12, at the location of its new site to celebrate the office and network with the TechBio community.

For more information on open positions and to apply, visit recursion.com/careers and valencelabs.com/careers.

About Recursion
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological, chemical and patient-centric datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, chemistry and patient-centric data to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.

Media Contact
Media@Recursion.com

Investor Contact
Investor@Recursion.com

Forward-Looking Statements
This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the opening of the London office and timing of such opening; the recruitment efforts and number of roles at the London office; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “could,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2023. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

GlobeNewswire Distribution ID 9060948

Campaign includes the groundbreaking WTA Foundation Global Women’s Health Fund, which aims to help at least 1 million women in its first year with an inaugural donation from WTA Tour title sponsor Hologic

St. Petersburg, Fla. and Seattle, March 08, 2024 (GLOBE NEWSWIRE) — Today, on International Women’s Day, the WTA Foundation and the Bill & Melinda Gates Foundation unveiled Women Change the Game, a new campaign uniting the power of women’s tennis and philanthropy to elevate women’s health and nutrition as a global priority. A key component of the campaign is the first-of-its-kind WTA Foundation Global Women’s Health Fund. With an inaugural donation from WTA Tour title sponsor Hologic, in its first year, the Fund will focus on a key aspect of preventive care: It aims to support at least one million women with prenatal vitamins in low- and middle-income countries where access to adequate nutrition for maternal health is limited.

“Throughout my life, tennis has given me a pathway to pursue my dreams, and I know first-hand how important it is to have access to the right health care and nutrition,” said Caroline Wozniacki, former WTA World No. 1 champion, and mother of two. “On International Women’s Day and beyond, I am proud to shine a light on women’s health and nutrition in the hopes that all women can reach their full power and potential.”

Women spend 25% more of their life in poor health than men, according to a 2024 report by the World Economic Forum. This significant health gap impacts women’s quality of life and limits their ability to engage in the workforce and earn a living for themselves and their families. And in the face of global crises—humanitarian disasters, war, and climate change—women and girls suffer the worst consequences.

“Every woman and girl deserves an equal opportunity to be her best—whether in school, at work, or on the tennis court,” said Naomi Osaka, four-time Grand Slam singles champion and new mom. “We are stepping up for women in need, because when we champion each other, we all win.”

Today, more than 1 billion women and girls lack access to the good nutrition and healthy diets they need to survive and thrive, with dire consequences for themselves and their children. Across the world, the gender nutrition gap is worsening. Women and girls are 50% more likely to suffer from malnutrition than boys and men. While the majority of expectant mothers in high-income countries take prenatal vitamins throughout their pregnancies, most women in low- and middle-income countries lack access to this simple, lifesaving resource. Prenatal vitamins provide key nutrients that dramatically reduce the risk of stillbirth, infant mortality, and babies born small and vulnerable, and they improve women’s health.

“It is unacceptable that so many women and girls don’t have access to adequate nutrition and basic care,” said Melinda French Gates, co-chair of the Bill & Melinda Gates Foundation. “The WTA Foundation was founded on the idea of equal opportunity, and that’s exactly what Women Change the Game is about. Nowhere is it more important to level the playing field than women’s health.”

Women Change the Game
Women Change the Game will engage global audiences through tennis—translating the power of elite athletes on the court into elite influence off the court—to take on some of the most pressing and urgent issues for women and girls. A critical component of the campaign is the new WTA Foundation Global Women’s Health Fund, which will mobilize resources for lifesaving women’s health and nutrition products and services that are readily available in high-income countries but are difficult to access or altogether unavailable in low- and middle-income countries.

The campaign features creative assets, including video, digital, and social content, that elevate the voices of elite women athletes in service of women’s equality and better health and nutrition for women worldwide. A series of activations across the Hologic WTA Tour will engage corporate sponsors, tournaments, philanthropic partners, athletes, and fans to raise awareness and funding for women’s health and nutrition. The campaign drives audiences to womenchangethegame.com to engage on the issues and donate.

The WTA Foundation Global Women’s Health Fund
The fundraising component of the partnership is the Global Women’s Health Fund, with the kick-off donation of $1.5 million coming from Hologic, title sponsor of the WTA Tour and one of the world’s top medical technology innovators focused on improving women’s health and well-being. Collaboration on the Fund marks the latest expansion of the WTA’s and Hologic’s comprehensive, multiyear alliance to elevate women’s well-being. The Fund leverages data insights from sources like the Hologic Global Women’s Health Index, which shows the interlocking importance of preventive care, access to adequate food and shelter, strong educational opportunities, and other critical resources for women and girls of all ages.

“Whether it’s prenatal vitamins for expectant mothers or routine screenings for breast and cervical cancers, we know that early intervention is pivotal to helping women live longer and better,” said Stephen P. MacMillan, chairman, president, and CEO of Hologic. “As the first donor to the Global Women’s Health Fund, we’re teaming up with the WTA Foundation and the Bill & Melinda Gates Foundation in urging others—businesses, foundations, governments, tennis fans—to join us in this crucial movement of improving women’s health.”

For at least the first year, every dollar raised through the Fund will be directed toward the Child Nutrition Fund, a global initiative aimed at ending child wasting led by UNICEF, with support from the U.K. government, the Children’s Investment Fund Foundation, the Bill & Melinda Gates Foundation, and other partners. UNICEF, a leader in global health and nutrition, has the worldwide footprint and local partnerships necessary to bring products and services directly into the hands of women in need around the world.

For more information about Women Change the Game and the WTA Foundation’s Global Women’s Health Fund, visit www.womenchangethegame.com.

About the WTA
Founded by Billie Jean King in 1973 on the principle of equal opportunity, the WTA is the global leader in women’s professional sports. The WTA is one of the world’s most recognizable and high-profile sports organizations, consisting of more than 1,600 players representing over 80 nations, all competing to earn WTA rankings points and prestigious tournament titles. The Hologic WTA Tour is comprised of over 70 events and four Grand Slams, spanning 30 countries and regions across six continents with a global audience of more than 1 billion. Further information on the WTA can be found at wtatennis.com.

About the WTA Foundation
Serving as the philanthropic arm of the leading women’s professional sport globally, the WTA Foundation empowers girls and women to live fully and supports our WTA communities worldwide through initiatives promoting equality, education, leadership, and health and wellness.

About the Bill & Melinda Gates Foundation
Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people’s health and giving them the chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people—especially those with the fewest resources—have access to the opportunities they need to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Mark Suzman, under the direction of Co-chairs Bill Gates and Melinda French Gates and the board of trustees.

Attachments

• Women Change the Game
• A New Partnership

WTA Foundation
wtacommunications@wtatennis.com

Bill & Melinda Gates Foundation
Media@gatesfoundation.org

GlobeNewswire Distribution ID 9060346